The largest-ever genetic study of fibromyalgia has identified 26 genomic variants associated with the condition, providing the strongest evidence to date that the chronic pain disorder originates primarily in the nervous system rather than as an autoimmune disease. Published on July 28, 2026, in Nature Medicine, the international research effort analyzed genetic data from more than 2.5 million adults across 11 cohorts in the United States, United Kingdom, Finland, Estonia, Denmark, and Iceland, according to findings detailed by researchers at Fred Hutch Cancer Center.
Neurological Roots Versus Autoimmune Theories
For decades, the existence of fibromyalgia—which affects roughly 2% of the global population with widespread pain, tenderness, fatigue, and sleep disturbances—has faced skepticism due to a lack of diagnostic biomarkers. According to Dr. Michael Wainberg, an investigator at the Lunenfeld-Tanenbaum Research Institute, part of Sinai Health and the University of Toronto and co-senior author of the study, the findings validate patient experiences. “For decades, patients have been dismissed or told their pain is simply psychological,” Dr. Wainberg stated, noting that the work confirms a clear biological basis for the condition. By integrating the genetic findings with a dataset of 20 million cells from various tissues, the research team found that genes near the identified fibromyalgia risk variants showed higher activity in nervous system cells than in other cell types, distinguishing the condition from classical autoimmune disorders.
Surprising Genetic Link to Huntington’s Disease
Among the 26 genetic variants discovered, the variant with the strongest association mapped directly within the HTT gene. Other types of mutations in this specific gene are well known to cause Huntington’s disease, a severe, progressive, and fatal neurodegenerative disorder. Additionally, the study pointed to a receptor designated as GPR52, which regulates HTT levels and is already under investigation as a potential drug target for Huntington’s disease. Despite these genetic discoveries, lead researchers emphasize that genetics alone does not determine whether an individual develops fibromyalgia. According to Dr. Nasa Sinnott-Armstrong at Fred Hutch Cancer Center and the University of Washington in Seattle, carriers of these genetic variants likely require an additional trigger, such as a painful arthritic condition, to activate the syndrome.
Overlap With Other Chronic Pain Syndromes
The study also uncovered substantial genetic overlap between fibromyalgia and several related conditions, including low back pain, irritable bowel syndrome, and post-traumatic stress disorder. According to Dr. Frances Williams, a rheumatologist at TwinsUK, King’s College London and co-author on the research, these shared biological mechanisms explain why chronic pain syndromes frequently cluster together within individuals and families. Researchers suggest that targeting these shared nervous system pathways could eventually yield treatments capable of addressing an entire cluster of overlapping disorders.
Related reading